within Pharmacolibrary.Drugs.ATC.C;

model C07AA17
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 70 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 4 / 1000000,
    adminCount     = 1,
    Vd             = 0.12,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0013333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Bopindolol is a non-selective beta-adrenergic blocker that was used for the treatment of hypertension and angina pectoris. It is a prodrug that is converted to its active metabolite, 4-hydroxybopindolol. Currently, bopindolol is not widely used or approved in many countries due to availability of newer beta-blockers and safety concerns.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from available literature. Parameters are for healthy adult subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Wensing, G, et al., &amp; Kirch, W (1990). Pharmacokinetics after a single oral dose of bopindolol in patients with cirrhosis. <i>European journal of clinical pharmacology</i> 39(6) 569–572. DOI:<a href=&quot;https://doi.org/10.1007/BF00316097&quot;>10.1007/BF00316097</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1982762/&quot;>https://pubmed.ncbi.nlm.nih.gov/1982762</a></p></li><li><p>MacDonald, NJ, et al., &amp; Elliott, HL (1991). The effect of renal impairment on the pharmacokinetics and metabolism of bopindolol. <i>British journal of clinical pharmacology</i> 31(6) 697–700. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1991.tb05596.x&quot;>10.1111/j.1365-2125.1991.tb05596.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1678272/&quot;>https://pubmed.ncbi.nlm.nih.gov/1678272</a></p></li><li><p>Aellig, WH, et al., &amp; Rosenthaler, J (1986). Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol. <i>British journal of clinical pharmacology</i> 21(1) 45–51. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1986.tb02821.x&quot;>10.1111/j.1365-2125.1986.tb02821.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2868747/&quot;>https://pubmed.ncbi.nlm.nih.gov/2868747</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C07AA17;
